ES2167555T3 - Triazolonas como inhibidores de la sintesis de apolipoproteina-b. - Google Patents
Triazolonas como inhibidores de la sintesis de apolipoproteina-b.Info
- Publication number
- ES2167555T3 ES2167555T3 ES96910968T ES96910968T ES2167555T3 ES 2167555 T3 ES2167555 T3 ES 2167555T3 ES 96910968 T ES96910968 T ES 96910968T ES 96910968 T ES96910968 T ES 96910968T ES 2167555 T3 ES2167555 T3 ES 2167555T3
- Authority
- ES
- Spain
- Prior art keywords
- rent
- replaced
- phenyl
- invention refers
- apolipoproteina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Seasonings (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Saccharide Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE FORMULA (I), DONDE R1 ES ALQUILO C1-10 , CICLOALQUILO C37 O ALQUILO C1-6 SUSTITUIDO CON CICLOALQUILO C3-7 ; R2 ES HIDROGENO O ALQUILO C1-6 ; ALK REPRESENTA ALCANODIILO C1-3 ; -A- REPRESENTA UN RADICAL DIVALENTE DE FORMULA: (A) - CH = CH - N = CH -, (B) - N = CH - N = CH -, (C) CH = N - N = CH -, (D) - CH = CH - CH = N -; EN DICHOS RADICALES DIVALENTES, UN ATOMO DE HIDROGENO PUEDE SER REEMPLAZADO POR UN ALQUILO C1-6 ; Y AR ES UN FENILO NO SUSTITU IDO; FENILO SUSTITUIDO CON HASTA DOS SUSTITUYENTES SELECCIONADOS DE ENTRE HALO, ALQUILO C1-6 O ALQUILOXI C1-6 ; N AFTILO NO SUSTITUIDO O NAFTILO SUSTITUIDO CON HASTA DOS SUSTITUYENTES SELECCIONADOS DE ENTRE HALO, ALQUILO C1-6 O ALQUILOXI C1-6 ; SUS FORMAS ISOMEROS ESTEREOQUIMICOS, Y SUS SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES. LA PRESENTE INVENCION SE REFIERE ADEMAS A LAS COMPOSICIONES FARMACEUTICAS QUE INCLUYEN COMPUESTOS DE FORMULA (I), SU PREPARACION ASI COMO SU USO COMO MEDICAMENTOS EN EL TRATAMIENTO DE LA HIPERLIPIDEMIA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95201010 | 1995-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2167555T3 true ES2167555T3 (es) | 2002-05-16 |
Family
ID=8220206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96910968T Expired - Lifetime ES2167555T3 (es) | 1995-04-20 | 1996-04-12 | Triazolonas como inhibidores de la sintesis de apolipoproteina-b. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US5922718A (es) |
| EP (1) | EP0871626B1 (es) |
| JP (1) | JP3782455B2 (es) |
| KR (1) | KR100413219B1 (es) |
| CN (1) | CN1076727C (es) |
| AT (1) | ATE208386T1 (es) |
| AU (1) | AU699313B2 (es) |
| CA (1) | CA2217632A1 (es) |
| CZ (1) | CZ291737B6 (es) |
| DE (1) | DE69616825T2 (es) |
| DK (1) | DK0871626T3 (es) |
| ES (1) | ES2167555T3 (es) |
| HK (1) | HK1012186A1 (es) |
| HU (1) | HUP9801056A3 (es) |
| IL (1) | IL117980A (es) |
| NO (1) | NO312415B1 (es) |
| NZ (1) | NZ305869A (es) |
| PL (1) | PL183737B1 (es) |
| PT (1) | PT871626E (es) |
| TW (1) | TW457240B (es) |
| WO (1) | WO1996033193A1 (es) |
| ZA (1) | ZA963152B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074474A2 (en) | 2002-03-01 | 2003-09-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| EP1515703A1 (en) | 2002-06-21 | 2005-03-23 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| US7598046B2 (en) * | 2003-06-19 | 2009-10-06 | Laboratories Serono Sa | Use of prion conversion modulating agents |
| EP1725870A1 (en) * | 2004-03-18 | 2006-11-29 | Applied Research Systems ARS Holding N.V. | Anti-lipid rafts antibodies |
| EP1742941A1 (en) * | 2004-04-22 | 2007-01-17 | Transform Pharmaceuticals, Inc. | Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
| EA201592157A1 (ru) | 2013-06-07 | 2016-05-31 | Дзе Калифорния Инститъют Фор Биомедикал Рисёрч | Низкомолекулярные ингибиторы фиброза |
| EP3169343B1 (en) | 2014-07-15 | 2020-03-25 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Isolated polypeptides of cd44 and uses thereof |
| JP6706023B2 (ja) | 2014-12-10 | 2020-06-03 | ザ・スクリップス・リサーチ・インスティテュート | 線維症の小分子阻害剤 |
| WO2018190352A1 (ja) | 2017-04-11 | 2018-10-18 | 三井化学アグロ株式会社 | ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3936470A (en) * | 1975-01-27 | 1976-02-03 | Janssen Pharmaceutica N.V. | 1,3-Dioxolan-2-ylmethylimidazoles |
| US4101666A (en) * | 1975-10-06 | 1978-07-18 | Janssen Pharmaceutica N.V. | 1-(2-Ar-4-R-1,3-dioxolan-2-ylmethyl)imidazoles |
| US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4321272A (en) * | 1980-08-25 | 1982-03-23 | Syntex (U.S.A.) Inc. | Derivatives of substituted N-alkylimidazoles |
| DE3144318A1 (de) * | 1981-11-07 | 1983-05-19 | Bayer Ag, 5090 Leverkusen | 2-imidazolylmethyl-2-phenyl-1, 3-dioxolane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
| US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| CA1292472C (en) * | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
| US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| NZ223799A (en) * | 1987-03-25 | 1989-12-21 | Janssen Pharmaceutica Nv | Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| DK0741737T3 (da) * | 1994-01-24 | 2000-05-22 | Janssen Pharmaceutica Nv | Vandopløslige antifugale azoler |
-
1996
- 1996-03-22 TW TW085103449A patent/TW457240B/zh not_active IP Right Cessation
- 1996-04-12 CN CN96193235A patent/CN1076727C/zh not_active Expired - Fee Related
- 1996-04-12 KR KR1019970706751A patent/KR100413219B1/ko not_active IP Right Cessation
- 1996-04-12 EP EP96910968A patent/EP0871626B1/en not_active Expired - Lifetime
- 1996-04-12 NZ NZ305869A patent/NZ305869A/en unknown
- 1996-04-12 WO PCT/EP1996/001585 patent/WO1996033193A1/en active IP Right Grant
- 1996-04-12 PL PL96322872A patent/PL183737B1/pl not_active IP Right Cessation
- 1996-04-12 AT AT96910968T patent/ATE208386T1/de not_active IP Right Cessation
- 1996-04-12 JP JP53146096A patent/JP3782455B2/ja not_active Expired - Fee Related
- 1996-04-12 DE DE69616825T patent/DE69616825T2/de not_active Expired - Fee Related
- 1996-04-12 PT PT96910968T patent/PT871626E/pt unknown
- 1996-04-12 CA CA002217632A patent/CA2217632A1/en not_active Abandoned
- 1996-04-12 DK DK96910968T patent/DK0871626T3/da active
- 1996-04-12 US US08/930,847 patent/US5922718A/en not_active Expired - Fee Related
- 1996-04-12 AU AU53998/96A patent/AU699313B2/en not_active Ceased
- 1996-04-12 ES ES96910968T patent/ES2167555T3/es not_active Expired - Lifetime
- 1996-04-12 HU HU9801056A patent/HUP9801056A3/hu unknown
- 1996-04-12 CZ CZ19973288A patent/CZ291737B6/cs not_active IP Right Cessation
- 1996-04-19 IL IL11798096A patent/IL117980A/xx not_active IP Right Cessation
- 1996-04-19 ZA ZA9603152A patent/ZA963152B/xx unknown
-
1997
- 1997-10-10 NO NO19974690A patent/NO312415B1/no unknown
-
1998
- 1998-12-15 HK HK98113362A patent/HK1012186A1/xx not_active IP Right Cessation
-
1999
- 1999-02-17 US US09/251,989 patent/US6197972B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996033193A1 (en) | 1996-10-24 |
| US5922718A (en) | 1999-07-13 |
| US6197972B1 (en) | 2001-03-06 |
| CN1181079A (zh) | 1998-05-06 |
| DE69616825T2 (de) | 2002-06-27 |
| CA2217632A1 (en) | 1996-10-24 |
| NZ305869A (en) | 1998-08-26 |
| NO974690D0 (no) | 1997-10-10 |
| DK0871626T3 (da) | 2002-02-25 |
| PL322872A1 (en) | 1998-03-02 |
| IL117980A (en) | 2000-02-17 |
| CZ291737B6 (cs) | 2003-05-14 |
| EP0871626A1 (en) | 1998-10-21 |
| EP0871626B1 (en) | 2001-11-07 |
| CN1076727C (zh) | 2001-12-26 |
| CZ328897A3 (cs) | 1998-01-14 |
| NO974690L (no) | 1997-10-10 |
| DE69616825D1 (en) | 2001-12-13 |
| PL183737B1 (pl) | 2002-07-31 |
| KR19980703346A (ko) | 1998-10-15 |
| PT871626E (pt) | 2002-04-29 |
| ATE208386T1 (de) | 2001-11-15 |
| KR100413219B1 (ko) | 2004-05-31 |
| HK1012186A1 (en) | 1999-07-30 |
| HUP9801056A3 (en) | 1999-09-28 |
| NO312415B1 (no) | 2002-05-06 |
| IL117980A0 (en) | 1996-08-04 |
| ZA963152B (en) | 1997-10-20 |
| TW457240B (en) | 2001-10-01 |
| AU699313B2 (en) | 1998-12-03 |
| AU5399896A (en) | 1996-11-07 |
| JP3782455B2 (ja) | 2006-06-07 |
| JPH11503739A (ja) | 1999-03-30 |
| HUP9801056A2 (hu) | 1999-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
| AR008577A1 (es) | Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion | |
| MX9204139A (es) | Nuevos derivados de bencimidazolona, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| BG93979A (bg) | Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| KR830006174A (ko) | 기관지 항경련성 화합물 제조방법 | |
| MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
| FI970317A (fi) | Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä | |
| MX9207335A (es) | Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene. | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| ES2167555T3 (es) | Triazolonas como inhibidores de la sintesis de apolipoproteina-b. | |
| AR040489A1 (es) | Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen | |
| ATE243215T1 (de) | Neue 2-decarboxy-2-phosphinico prostaglandin f analoge | |
| NO20074622L (no) | Metabolitter for NK-1 antagonister for brekninger | |
| DK160297C (da) | N-acyl-arylamin-derivater samt deres fremstilling og anvendelse som mikrobicider | |
| BR0312176A (pt) | Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario | |
| BR0312175A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso | |
| AR004726A1 (es) | Derivados 25-hidroxi-16-eno-26,27-bis homo-colecalciferol, compuestos intermediarios para su preparacion, composiciones farmaceuticas que loscontienen y uso de dichos derivados para fabricar un medicamento. | |
| AR002264A1 (es) | 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario. | |
| HUP0203118A2 (hu) | Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0200783A2 (hu) | Maduraftalazinszármazékok alkalmazása gyulladást okozó citokinin inhibitor hatású gyógyszerkészítmények előállítására | |
| NO924806L (no) | Etanoladdukter av 6-sulfonylsubstituerte 3-hydroksykromaner og deres anvendelse som inhalasjonsmiddel ved sykdommer | |
| ES2183500T3 (es) | Nuevos compuestos y composiciones farmaceuticas que los contienen. |